73/100BGSK stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for GSK is 57.95, 15.1% above the current price of 50.33. Their targets range from 55.90 to 60.00.
Of the 2 firms that rated GSK in the past 12 months, 0 rate it buy or strong buy, 1 hold and 1 sell or strong sell (each firm at its latest rating): a Hold consensus.
Analysts' 1-year price targets range from 55.90 to 60.00, with an average of 57.95.
| Buy | 0 | |
| Hold | 1 | |
| Sell | 1 |
12-month price target
| Highest target | 60.00 |
| Average target | 57.95 |
| Lowest target | 55.90 |
| Current price | 50.33 |
GSK price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their GSK price target and rating?
How analysts rate GSK, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
0 of 2 firms rate it buy now, against 0 of 1 in January 2026.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
GSK analyst upgrades, downgrades and price targets
The latest rating change came on 29 October 2026, when Jefferies downgraded GSK from Buy to Hold. Its price target is 55.90.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 29 Oct 2026 | Jefferies | Downgraded · Buy → Hold | 55.90 | — | 48.74 |
| 15 Sept 2026 | Berenberg Bank Kerry Holford | — | 60.00 | — | 50.05 |
| 6 Jan 2026 | Barclays | Downgraded · Equal Weight → Underweight | — | — | — |
GSK EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect GSK's EPS to grow 12.5% a year until 2028. Over the last 5 years it fell 0.6% a year, and over the last 3 years it fell 27.6%.
Analysts expect GSK's revenue to grow 4.1% a year until 2028, about as fast as over the last 5 years (6.0% a year) and the last 3 years (3.7%).
Revenue
EPS
Does GSK beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 12.1% off the result, either way, and their revenue estimate 2.9%, over the last 12 quarters.
- EPS beats
- 61 / 98
- Revenue beats
- 19 / 32
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +12.1%
- Since
- August 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 28 Oct 2026 | 1.40 | 1.47 | +5.0% | 11.78B | 11.82B | +0.4% |
| Q2 FY2026 | 28 Jul 2026 | 1.27 | 1.36 | +7.1% | 11.02B | 11.18B | +1.4% |
| Q1 FY2026 | 29 Apr 2026 | 1.16 | 1.24 | +6.9% | 10.23B | 10.30B | +0.7% |
| Q4 FY2025 | 4 Feb 2026 | 0.64 | 0.68 | +6.3% | 11.41B | 11.78B | +3.2% |
| Q3 FY2025 | 29 Oct 2025 | 1.26 | 1.48 | +17.5% | 11.04B | 11.32B | +2.6% |
| Q2 FY2025 | 30 Jul 2025 | 1.12 | 1.23 | +9.8% | 10.50B | 10.61B | +1.1% |
| Q1 FY2025 | 30 Apr 2025 | 1.08 | 1.13 | +4.6% | 9.72B | 10.04B | +3.3% |
| Q4 FY2024 | 5 Feb 2025 | 0.44 | 0.59 | +34.1% | 9.54B | 10.16B | +6.5% |
| Q3 FY2024 | 30 Oct 2024 | 1.16 | 1.27 | +9.5% | 10.52B | 10.42B | -0.9% |
| Q2 FY2024 | 31 Jul 2024 | 1.00 | 1.09 | +9.0% | 9.57B | 10.13B | +5.8% |
| Q1 FY2024 | 1 May 2024 | 0.91 | 1.09 | +19.8% | 8.89B | 9.20B | +3.4% |
| Q3 FY2023 | 1 Nov 2023 | 1.09 | 1.26 | +15.6% | 9.37B | 9.88B | +5.4% |
GSK stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If GSK's earnings keep growing at the 5.4% a year analysts expect to FY2028, it would earn about 5.87 a share in FY2030. At the P/E it has traded at over the last five years (3.9 to 21.4) that is 22.92 to 125.90 a share, or 77.81 at its average P/E of 13.3. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 4.84 | 18.90 | 64.18 | 103.85 |
| FY2027 | 5.04 | 19.66 | 66.76 | 108.02 |
| FY2028 | 5.29 | 20.64 | 70.09 | 113.40 |
| FY2029 (extrapolated) | 5.57 | 21.75 | 73.85 | 119.49 |
| FY2030 (extrapolated) | 5.87 | 22.92 | 77.81 | 125.90 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 5.4% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (3.9, 13.3, 21.4).
Is GSK stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
GSK's P/E of 17.4 is near the top of its 5-year range (3.3 to 25.3, median 13.4). Analysts expect faster growth than in recent years, which can explain part of the high P/E. At the median P/E of its peers (23.2 × EPS of 2.85), GSK's fair value is 66.10; the price, 50.33, is 23.9% below it. The EPS is without 0.02 a share of one-off gains in its other income, which the business does not repeat. Its forward P/E, on the consensus for FY2026, is 10.4.
Fair value on the peers is the median P/E of the US companies of its industry closest in size times its earnings per share of the last twelve months; the ends of the bar are the same earnings at the lowest and highest peer P/E (18.3 and 32.3). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 17.44
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 13.42
- Five-year P/E range
- 3.3 – 25.3
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 10.40
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 3.25
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +15.1%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 99.090 | 194.93146Price 99.09244 | +96.7% | |
| 42.225 | 82.9546Price 42.23165 | +96.4% | |
| 186.680 | 360.82271Price 186.68451 | +93.3% | |
| 213.670 | 405.57304Price 213.67507 | +89.8% | |
| 161.160 | 305.51157Price 161.16396 | +89.6% | |
| 160.650 | 300.09225Price 160.65375 | +86.8% | |
| 165.860 | 308.95212Price 165.86442 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.